Long-acting GLP-1s (including Victoza, Trulicity, Bydureon, Ozempic, and Rybelsus) work to lower both post-meal and fasting blood sugar levels
Initial results reported that phase I metabolism of the nootropic was very low with an intrinsic clearance of 2.72 ul/min/mg, as well as an average half life of approximately 510 minutes
Instead, fasting hyperglucagonaemia appears to be associated with hepatic insulin resistance or, as shown in other studies, hepatic steatosis [83, 100]
Enhanced mitochondrial biogenesis is associated with increased expression of the mitochondrial ATP-dependent Lon protease
These products are not approved for, and may not be used in, diagnostic, therapeutic, or clinical procedures, or for administration to humans or animals under any circumstances